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Molecular characterization of a patient presumed  
to Have prader-Willi syndrome
Marina Falaleeva1, Carlos R. Sulsona2, Horst R. Zielke3, Kathleen M. Currey3, pierre de la Grange4, 
Vahid Aslanzadeh1, Daniel J. Driscoll2 and Stefan Stamm1
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Abstract: Prader-Willi syndrome (PWS) is caused by the loss of RNA expression from an imprinted region on chromosome 15 that 
includes SNRPN, SNORD115, and SNORD116. Currently, there are no mouse models that faithfully reflect the human phenotype and 
investigations rely on human post-mortem material. During molecular characterization of tissue deposited in a public brain bank from 
a patient diagnosed with Prader-Willi syndrome, we found RNA expression from SNRPN, SNORD115, and SNORD116 which does 
not support a genetic diagnosis of Prader-Willi syndrome. The patient was a female, Caucasian nursing home resident with history of 
morbid obesity (BMI 56.3) and mental retardation. She died at age of 56 from pulmonary embolism. SNORD115 and SNORD116 are 
unexpectedly stable in post mortem tissue and can be used for post-mortem diagnosis. Molecular characterization of PWS tissue donors 
can confirm the diagnosis and identify those patients that have been misdiagnosed.
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Introduction
Prader-Willi syndrome (PWS) is a congenital disease 
caused by the loss of RNA expression from an imprinted 
region on chromosome 15. This region is expressed only 
from the paternally inherited allele. Patients with PWS 
typically undergo several stages beginning as infants 
when they are characterized by severe infantile hypo-
tonia with poor suck and failure to thrive. This stage is 
followed by early childhood onset obesity and hyper-
phagia. The patients exhibit developmental delay and/or 
mild intellectual disability. Other features include short 
stature, hypogonadism, thick saliva, obsessive-compul-
sive behavior, and hormonal imbalances.1,2
Recently, several patients with Prader-Willi-like 
 phenotypes have been described (Fig. 1A). These 
patients had microdeletions affecting two clusters of 
small  nucleolar RNAs (snoRNAs), SNORD115 and 
SNORD116. This indicates that the loss of  snoRNAs 
plays a central role in the etiology of the disease 
(Fig. 1A).3–5
The molecular mechanisms that link the loss of 
two clusters of snoRNAs to the disease are currently 
under investigation. Loss of SNORD115 could explain 
hyperphagia observed in PWS patients, as SNORD115 
has been shown to regulate alternative splicing of the 
serotonin receptor 2C. SNORD115 helps to generate 
the most active form of the receptor.6–8 No molecular 
mechanisms have been established thus far demon-
strating the role of SNORD116 in the generation of 
PWS. It is known, however, that SNORD116 influ-
ences the expression of microRNAs hosted in the 
second exon of the serotonin receptor 2C.9
SNORD115 and SNORD116 do not express 
canonical C/D box snoRNAs, but are likely processed 
into shorter RNAs, termed psnoRNAs,10,11 that do not 
associate with the proteins typically found in C/D box 
snoRNAs.10,12 Canonical C/D box snoRNAs function 
in 2′-O-methylation of non-coding RNAs and form a 
defined ribonuclear complex with the proteins fibril-
larin, NOP56/58 and 15.5 kD (NHP2L1).
Currently, there are no mouse models available that 
faithfully replicate the human phenotype13 and molec-
ular investigations rely on human material. Since 
SNORD115 is exclusively, and SNORD116 mainly, 
expressed in the brain, tissue deposited in brain banks 
is crucial for molecular analysis aimed to find the 
cause of the disease.
case presentation
Patient 4876 was clinically diagnosed with PWS and 
lived in group housing. The patient’s cause of death 
was pulmonary embolism at the age of 56 years 
(year of birth 1950). She was described as morbidly 
obese with a weight of 140 kg (308 lbs) and height of 
157.5 cm (5 ft, 2 in) with a body mass index (BMI) 
of 56.3. She had a life long history of learning dif-
ficulties, carrying a diagnosis of mental retardation. 
She was reported to have an insatiable appetite, con-
tinually seeking food. On one occasion, she ingested 
5 lbs of raw hamburger meat. It was necessary to 
lock food sources and as such, the refrigerator had a 
chain and lock on it. She threw extreme temper tan-
trums when she was denied food. Medical records are 
sparse, but she was reported to suffer from  anxiety 
Patient 1
Patient 2
Patient 3
A
Figure 1A. overview of the snoRNA expression region on chromosome 15. Summary of the prader-Willi syndrome region on chromosome 15q11.2-q13. 
C/D box snoRNAs are indicated as SNoRD and their gene number. 
notes: The SNoRD116 cluster consists of 24 expression units and the SNoRD115 cluster of 47 expression units and is indicated in yellow. IpW: imprinted 
in prader-Willi. Microdeletion of snoRNA expressing units that cause pWS are indicated by arrows. patient 1,3 patient 2,5 patient 3.4 The sequences for the 
snoRNA probes were gggtcaatgatgagaaccttatattgtcctgaagagaggtgatgacttaaaaatcatgctcaataggattacgctgaggccc for SNoRD115-11 and GGACCTCAGT-
TCCGATGAGAACGACGGTATGAGTTCTCACTCATTTTGTTC AGCTTTTCCAAGGAATGTTTTTATGGGGGACTCATCATCGATCCA for SNoRD116-3.
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and have  frequent falls. The frequent falls may have 
been due to low muscle tone and decreased muscle 
mass that is described in PWS. Additionally, the 
anxiety may have contributed to her behavior prob-
lems and are usually described in PWS patients. This 
patient also had Obstructive Sleep Apnea (OSA) 
with chronic CO2 retention, also described in PWS 
patients.  Morbid obesity is also associated with 
OSA, however, PWS patients have a low muscle tone 
in addition to obesity that increases odds for OSA. 
These described clinical features led to the diagnosis 
of PWS for this patient. This diagnosis was based on 
clinical criteria since, at the time, routine diagnostic 
tests were not available.
The brain was removed after a post mortem inter-
val of 41 hrs and showed no gross abnormalities. 
 Microscopic examination showed gliosis and deposi-
tion of dark granular material in the cerebral cortical 
molecular layer and in the midbrain. There were no 
observable neurofibrillary tangles, senile plaques, or 
Lewy bodies. There was multifocal leptomeningeal 
fibrosis. The dentate gyrus showed focal thinning and 
dispersion of neurons, some of which showed degen-
erative features. There was loss of Purkinje cells 
and Bergmann’s gliosis. The patient’s medical his-
tory included depression, mental retardation, morbid 
obesity, hypothyroidism, diabetes mellitus, history 
of falls, chronic CO2 retention secondary to obesity, 
hypercholesterolemia, recent urinary tract infections, 
and meningioma. Additional family history was 
obtained following the current genetic analysis. The 
donor had two sisters with the same phenotype, one 
of whom is deceased.
post-Mortem Genetic evaluation
The brain of patient 4876 was donated to the NICHD 
Brain and Tissue Bank (Baltimore, MD). We analyzed 
RNA from frontal cortex by RNase protection analysis. 
As a probe, we used a uniformly radiolabeled riboprobe 
against chr15: 25, 318, 253-25, 318, 349 for SNORD115 
and chr15: 25, 494, 345-25, 494, 426 for SNORD116 
in Hg19 for SNORD115 and chr15: 25, 494, 345-25, 
494, 426 for SNORD116. The RNase protections were 
performed as previously described.14 RNA was iso-
lated from brain using RNeasy Lipid Tissue Kit (Qia-
gen, Hilden) according to manufactory protocol. RNA 
expressing constructs to make RNase protection probes 
are available through Addgene (Cambridge MA).
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Figure 1B. overview of the snoRNA expression region on chromosome 
15. RNase protection analysis of 10 µg frontal cortex RNA from pWS 
patients and control patients. 
notes: As a probe, uniformly 32p-labeled antisense probes were used. 
The RNA marker is 150, 100, 90, 80, 70, 60, 50, 40 and 30 nt. The car-
toon on the right shows the localization of the riboprobes and the outline 
of an RNase protection assay.
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Figure 1c. overview of the snoRNA expression region on chromosome 15. 
RNase protection analysis of 10 µg frontal cortex RNA from pWS and con-
trol patients using a U2 riboprobe with the sequence ATCGCTTCTCG-
GCCTTTTGGCTAAGATCAAGTGTAGTATCTGTTCTTATCAGT 
TTAATATCTGATACGTCCTCTATCCGAGGACAATATATTAAATGGATTTTTGG 
AAATAGGAGATGGAATAGGAGCTTGCTCCGTCCACTCCACGCATC-
GACCTG GTATTGCAGTACTTCCAGGAACGGTGCACTCTCC.
note: U2 expresses multiple related genes, which accounts for the 
additional bands.
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As controls, we used RNA obtained from non 
Prader-Willi subject tissues from the NICHD brain 
bank (Table 1).
As shown in Figure 1B, patient 4876 expressed 
SNORD115 and SNORD116 to the same degree 
as the controls. Performing an RNase protection 
assay with the ubiquitously expressed U2 snoRNA 
showed approximately equal loading in each lane 
(Fig. 1C).
Next, the expression of small nuclear ribonucleopro-
tein polypeptide N (SNRPN) that hosts SNORD115 and 
SNORD116 in their 3′ UTR was analyzed (Fig. 2). We 
amplified the SNRPN cDNA using primers h_SNRPN-F 
ggactcccatcaagtctcca h (to exon #4) SNRPN-R tggctt-
taaccacctcttgg (to exon #5). Again, there was expression 
of SNRPN in patient 4876, but not in PWS controls.
Quantitative (q) RT-PCR was conducted for each 
of the brain tissue samples using 400 ng of total 
Table 1. overview of patient material used.
patient 4876 5324 4805 5238 4782 1539
Sex Female Male Female Male Male Female
Age 56 18 39 32 18 33
Cause of  
death
pulmonary embolism  
(diagnosed with pWS)
Complications of 
disorder (pWS)
Ischemic  
bowel (pWS)
Morphine 
intoxication
Head and  
chest injuries
Multiple 
injuries
pMI, hours 41 22 16 7 17 23
RIN 2,3 5,9 3,9 4,1 8,9 7,5
Abbreviations: pMI, post mortem interval; RIN number (RNA integrity number) determined by capillary electrophoresis.
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
4.50
5.00
PWS 4805
(mat UPD 15)
PWS 4876
(not PWS)
PWS 5324
(atypical pat del)
Control 1539 Control 4782 Control 5238 PB 264S1
(7 yrs)
PB 282S1
(14 yrs)
PB 343S1
(24 yrs)
F
o
ld
 c
h
an
g
e 
in
 g
en
e 
ex
p
re
ss
io
n
Brain tissue
SNRPN
SNORD116
Peripheral blood
D
Figure 1D. overview of the snoRNA expression region on chromosome 15. qRT-pCR analysis of SNoRD116 and SNRpN expression in a cortex of pWS 
and normal subjects.
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RNA, with a net final RNA concentration per  reaction 
of 20 ng/µl. Then, 2.5 µl of the cDNA prod-
uct  (approximately 50 ng of cDNA) was used for 
quantitative PCR (qPCR) using TaqMan Probes 
directed at the SNORD116 (custom probe) and 
SNRPN (Applied Biosystems) target sites. A GAPDH 
TaqMan Probe (Applied Biosystems) was used as 
loading control. As shown in Figure 1D, patient 4876 
had expression at SNRPN that was more than any of 
the 3  control brain samples and a very robust expres-
sion at SNORD116. In contrast, the two PWS sam-
ples (4805 and 5324) had basically no expression at 
SNRPN and SNORD116.
DNA methylation analysis using Methylation-
 Specific Multiplex Ligation-Dependent Probe 
Amplification (MS-MLPA) can be used to diagnose 
individuals with PWS.1 We used 100 ng of DNA for 
each of the brain tissue samples, according to the 
manufacturer’s instructions (MRC Holland; Amster-
dam, Netherlands). Our analysis showed that patient 
4876 had approximately 57% DNA methylation at 
MKRN3, which would be typical for a normal control 
individual and was within the range of 3 control brain 
samples15 (Table 2). DNA methylation analysis at the 
SNRPN locus could not be determined due to DNA 
degradation from the aged brain sample.
Finally, we performed Affymetrix exon junction 
array analysis using posterior hypothalamic RNA. We 
compared genome wide gene expression of patient 
4876, with the two molecularly confirmed PWS 
patients 5324 and 4805, as well as the controls (5238, 
4782, and 1539) (Table 1). For the analysis, the mean 
values in the control and PWS groups were compared 
with the values obtained for patient 4876. The array 
analysis is shown in the supplementary files 1 and 2 
as excel spreadsheets.
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Figure 2. RT-pCR analysis of the SNRpN gene (A) 1 µg of RNA was 
reverse transcribed and amplified with the primers h_SNRPN-F ggactc-
ccatcaagtctcca h (to exon #4) SNRpN-R tggctttaaccacctcttgg (to exon 
#5) that detect snRNpN. (B) TRAK2 mRNA amplification was used as a 
loading control.
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The most distinct difference between 4876 and the 
two PWS samples were RNAs expressed from the 
PWS critical region on chromosome 15 that showed 
more than a 20 fold change. This finding is supported 
by RNase protection of SNORD115 and SNORD116, 
as well as the RT-PCR analysis of SNRPN. Overall 
we observed 7,190 changes between patient 4876 and 
PWS subjects.
The comparison between 4876 and control patients 
resulted in 18,050 changes with a significant change 
in expression. The high number of changes in both 
experiments likely indicates differences between 
individuals, rather than differences due to brain 
 pathology. However, the RNA from posterior hypo-
thalamus of patient 4876 was more similar to PWS 
subjects than to the control, as indicated by the lower 
numbers of fold changes.
conclusion
Patient 4876 was diagnosed with PWS because of 
typical clinical demonstrations such as hyperphagia, 
morbid obesity, short statue, low muscle tone, sleep 
apnea, and mental retardation. No modern genetic 
analysis has been performed while the patient was 
alive. However, our post-mortem molecular genetic 
analyses eliminate PWS as a diagnosis. Our genetic 
analysis is based on the copy number of genes in the 
genetic region causing the disease as well as expres-
sion of SNORD115 and SNORD116 snoRNAs. Due 
to the long post mortem interval of 41 hrs, the DNA 
was damaged and did not yield complete DNA methy-
lation results for all genes of the PWS critical region. 
Similarly, the RNA was degraded with an RNA integ-
rity number (RIN) of 2.3 for patient 4876.
The low RIN indicates a relatively high level of 
degradation of ribosomal RNAs, as RIN quantification 
relies on ratio of long ribosomal RNA and short RNAs. 
snoRNAs appear to be fairly stable, as we could detect 
them using RNase protection analysis and qRT-PCR in 
RNA with a high degree of degradation. This could be 
due to posttranscriptional modifications or their small 
size. In contrast to qPCR, RNase protection analysis 
can discriminate between related copies of SNORD115 
and SNORD116. In addition the technique allows abso-
lute quantification of RNA and can be performed using 
commercially available kits. Thus using RNase protec-
tion and qRT-PCR, SNORD115 and SNORD116 can 
be detected in post-mortem tissue.
A genome wide array analysis showed that in terms 
of RNA expression, patient 4876 was more similar to 
PWS subjects than the genetically normal controls. 
This similarity reflects the clinical phenotype where 
patient 4876 was clinically similar to PWS resulting 
in misdiagnosis. Due to the small sample number, 
which is an intrinsic problem of using post-mortem 
tissue of a rare disease, we cannot make statisti-
cally supported analyses. However, the data suggest 
that some obesity syndromes have similarities with 
PWS, although the basic molecular defect is clearly 
different.
Our findings point out that diagnosis of patients 
based on clinical phenotype may result in  misdiagnosis. 
Although clinical records are necessary and helpful, 
genetic analysis of tissues donated for research should 
be performed when feasible.
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